[SCHEDULE 13G/A] Lexeo Therapeutics, Inc. SEC Filing
Citadel-linked entities disclose a substantial passive stake in Lexeo Therapeutics (LXEO). Collectively, Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC report beneficial ownership of 5,325,269 shares, representing 9.6% of outstanding shares on a fully calculated basis of 55,718,516 shares (including 1,717,302 shares issuable upon warrant conversion). Citadel Securities entities separately report 8,843 shares. Kenneth Griffin is reported to beneficially own 5,334,112 shares (also 9.6%). The filing states the positions were not acquired to change or influence control and identifies the reporting persons, organization structure and shared voting/dispositive powers.
Soggetti collegati a Citadel comunicano una partecipazione passiva rilevante in Lexeo Therapeutics (LXEO). Insieme, Citadel Advisors LLC, Citadel Advisors Holdings LP e Citadel GP LLC dichiarano la titolarit脿 beneficiaria di 5.325.269 azioni, pari a il 9,6% delle azioni in circolazione su una base totalmente diluita di 55.718.516 azioni (incluse 1.717.302 azioni emettibili a seguito della conversione di warrant). Entit脿 di Citadel Securities riportano separatamente 8.843 azioni. Kenneth Griffin risulta titolare beneficiario di 5.334.112 azioni (anch鈥檈gli il 9,6%). La comunicazione precisa che le posizioni non sono state acquisite con l鈥檌ntento di modificare o influenzare il controllo e indica le persone che presentano la dichiarazione, la struttura organizzativa e i poteri di voto/disposizione condivisi.
Entidades vinculadas a Citadel revelan una participaci贸n pasiva considerable en Lexeo Therapeutics (LXEO). En conjunto, Citadel Advisors LLC, Citadel Advisors Holdings LP y Citadel GP LLC informan la propiedad beneficiaria de 5.325.269 acciones, lo que representa el 9,6% de las acciones en circulaci贸n sobre una base totalmente diluida de 55.718.516 acciones (incluidas 1.717.302 acciones susceptibles de emitirse por conversi贸n de warrants). Entidades de Citadel Securities informan por separado 8.843 acciones. Se comunica que Kenneth Griffin posee beneficiariamente 5.334.112 acciones (tambi茅n el 9,6%). El expediente afirma que las posiciones no se adquirieron para cambiar o influir en el control e identifica a las personas informantes, la estructura organizativa y los poderes compartidos de voto/disposici贸n.
鞁滍儉雿� 甏�霠� 氩曥澑霌れ澊 霠夓嫓鞓� 韰岆澕頁嫳鞀�(LXEO)鞐� 雽�頃� 靸侂嫻頃� 靾橂彊鞝� 歆�攵勳潉 瓿店皽頄堨姷雼堧嫟. 歆戧硠頃橂┐ Citadel Advisors LLC, Citadel Advisors Holdings LP 氚� Citadel GP LLC電� 5,325,269欤茧ゼ 鞁れ 靻岇湢頃橁碃 鞛堧嫟瓿� 氤搓碃頄堨溂氅�, 鞚措姅 鞗岆煱韸� 鞝勴櫂鞙茧 氚滍枆霅� 靾� 鞛堧姅 1,717,302欤茧ゼ 韽暔頃� 鞕勳爠 頋劃 旮办 55,718,516欤� 欷� 9.6%鞐� 頃措嫻頃╇媹雼�. Citadel Securities 瓿勳棿靷姅 氤勲弰搿� 8,843欤茧ゼ 氤搓碃頄堨姷雼堧嫟. Kenneth Griffin鞚� 5,334,112欤�(鞐嫓 9.6%)毳� 鞁れ 靻岇湢頃� 瓴冹溂搿� 氤搓碃霅╇媹雼�. 鞝滌稖靹滊姅 鞚措煬頃� 歆�攵勳澊 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲媹霛缄碃 氚濏瀳氅�, 氤搓碃 欤检泊, 臁办 甑“ 氚� 瓿惦彊 鞚橁舶/觳橂秳 甓岉暅鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
Des entit茅s li茅es 脿 Citadel divulguent une participation passive substantielle dans Lexeo Therapeutics (LXEO). Collectivement, Citadel Advisors LLC, Citadel Advisors Holdings LP et Citadel GP LLC d茅clarent la propri茅t茅 b茅n茅ficiaire de 5 325 269 actions, repr茅sentant 9,6 % des actions en circulation sur une base enti猫rement dilu茅e de 55 718 516 actions (y compris 1 717 302 actions susceptibles d鈥櫭猼re 茅mises en conversion de bons). Des entit茅s de Citadel Securities d茅clarent s茅par茅ment 8 843 actions. Kenneth Griffin est d茅clar茅 d茅tenteur b茅n茅ficiaire de 5 334 112 actions (茅galement 9,6 %). le d茅p么t indique que ces positions n鈥檕nt pas 茅t茅 acquises dans le but de modifier ou d鈥檌nfluencer le contr么le et identifie les d茅clarants, la structure organisationnelle ainsi que les pouvoirs partag茅s de vote/disposition.
Mit Citadel verbundene Einheiten legen einen erheblichen passiven Anteil an Lexeo Therapeutics (LXEO) offen. Gemeinsam melden Citadel Advisors LLC, Citadel Advisors Holdings LP und Citadel GP LLC die wirtschaftliche Eigent眉merschaft von 5.325.269 Aktien, was 9,6 % der ausstehenden Aktien auf vollst盲ndig verw盲sserter Basis von 55.718.516 Aktien entspricht (einschlie脽lich 1.717.302 Aktien, die bei Wandlung von Warrants ausgebbar sind). Citadel Securities-Einheiten melden separat 8.843 Aktien. Kenneth Griffin wird mit 5.334.112 Aktien wirtschaftlich beg眉nstigt dargestellt (ebenfalls 9,6 %). Die Meldung gibt an, dass die Positionen nicht erworben wurden, um Kontrolle zu 盲ndern oder zu beeinflussen, und nennt die meldenden Personen, die Organisationsstruktur sowie gemeinsame Stimm- und Verf眉gungsrechte.
- Material ownership disclosed: Citadel-affiliated entities report a clear 9.6% beneficial stake in LXEO, improving market transparency
- Detailed ownership structure: Filing identifies specific entities, shared voting and dispositive powers, and inclusion of shares issuable upon warrant conversion
- Passive intent certified: Reporting persons certify the holdings were not acquired to change or influence control, consistent with Schedule 13G treatment
- None.
Insights
TL;DR: Citadel affiliates disclosed a sizable 9.6% passive stake in LXEO, a material ownership position that increases institutional concentration.
The Schedule 13G shows a nearly 10% position held collectively by Citadel-managed funds and related entities, using a 55.7 million share base that includes convertible warrants. For investors this raises institutional concentration and potential liquidity considerations; the filing characterizes the stake as passive under Section 13(g), which implies no intent to influence control. The precise share counts and shared voting/dispositive powers are disclosed, improving transparency around ownership structure.
TL;DR: A 9.6% disclosure is material for governance monitoring but the filer affirms passive intent under Schedule 13G.
The document identifies the reporting chain (portfolio manager, holding companies, GP entities, and Kenneth Griffin) and quantifies shared voting and dispositive power, which is important for directors and governance committees tracking influential holders. The explicit certification that shares were not acquired to change control reduces immediate takeover or activist signaling, though the position size warrants ongoing disclosure monitoring.
Soggetti collegati a Citadel comunicano una partecipazione passiva rilevante in Lexeo Therapeutics (LXEO). Insieme, Citadel Advisors LLC, Citadel Advisors Holdings LP e Citadel GP LLC dichiarano la titolarit脿 beneficiaria di 5.325.269 azioni, pari a il 9,6% delle azioni in circolazione su una base totalmente diluita di 55.718.516 azioni (incluse 1.717.302 azioni emettibili a seguito della conversione di warrant). Entit脿 di Citadel Securities riportano separatamente 8.843 azioni. Kenneth Griffin risulta titolare beneficiario di 5.334.112 azioni (anch鈥檈gli il 9,6%). La comunicazione precisa che le posizioni non sono state acquisite con l鈥檌ntento di modificare o influenzare il controllo e indica le persone che presentano la dichiarazione, la struttura organizzativa e i poteri di voto/disposizione condivisi.
Entidades vinculadas a Citadel revelan una participaci贸n pasiva considerable en Lexeo Therapeutics (LXEO). En conjunto, Citadel Advisors LLC, Citadel Advisors Holdings LP y Citadel GP LLC informan la propiedad beneficiaria de 5.325.269 acciones, lo que representa el 9,6% de las acciones en circulaci贸n sobre una base totalmente diluida de 55.718.516 acciones (incluidas 1.717.302 acciones susceptibles de emitirse por conversi贸n de warrants). Entidades de Citadel Securities informan por separado 8.843 acciones. Se comunica que Kenneth Griffin posee beneficiariamente 5.334.112 acciones (tambi茅n el 9,6%). El expediente afirma que las posiciones no se adquirieron para cambiar o influir en el control e identifica a las personas informantes, la estructura organizativa y los poderes compartidos de voto/disposici贸n.
鞁滍儉雿� 甏�霠� 氩曥澑霌れ澊 霠夓嫓鞓� 韰岆澕頁嫳鞀�(LXEO)鞐� 雽�頃� 靸侂嫻頃� 靾橂彊鞝� 歆�攵勳潉 瓿店皽頄堨姷雼堧嫟. 歆戧硠頃橂┐ Citadel Advisors LLC, Citadel Advisors Holdings LP 氚� Citadel GP LLC電� 5,325,269欤茧ゼ 鞁れ 靻岇湢頃橁碃 鞛堧嫟瓿� 氤搓碃頄堨溂氅�, 鞚措姅 鞗岆煱韸� 鞝勴櫂鞙茧 氚滍枆霅� 靾� 鞛堧姅 1,717,302欤茧ゼ 韽暔頃� 鞕勳爠 頋劃 旮办 55,718,516欤� 欷� 9.6%鞐� 頃措嫻頃╇媹雼�. Citadel Securities 瓿勳棿靷姅 氤勲弰搿� 8,843欤茧ゼ 氤搓碃頄堨姷雼堧嫟. Kenneth Griffin鞚� 5,334,112欤�(鞐嫓 9.6%)毳� 鞁れ 靻岇湢頃� 瓴冹溂搿� 氤搓碃霅╇媹雼�. 鞝滌稖靹滊姅 鞚措煬頃� 歆�攵勳澊 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲媹霛缄碃 氚濏瀳氅�, 氤搓碃 欤检泊, 臁办 甑“ 氚� 瓿惦彊 鞚橁舶/觳橂秳 甓岉暅鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
Des entit茅s li茅es 脿 Citadel divulguent une participation passive substantielle dans Lexeo Therapeutics (LXEO). Collectivement, Citadel Advisors LLC, Citadel Advisors Holdings LP et Citadel GP LLC d茅clarent la propri茅t茅 b茅n茅ficiaire de 5 325 269 actions, repr茅sentant 9,6 % des actions en circulation sur une base enti猫rement dilu茅e de 55 718 516 actions (y compris 1 717 302 actions susceptibles d鈥櫭猼re 茅mises en conversion de bons). Des entit茅s de Citadel Securities d茅clarent s茅par茅ment 8 843 actions. Kenneth Griffin est d茅clar茅 d茅tenteur b茅n茅ficiaire de 5 334 112 actions (茅galement 9,6 %). le d茅p么t indique que ces positions n鈥檕nt pas 茅t茅 acquises dans le but de modifier ou d鈥檌nfluencer le contr么le et identifie les d茅clarants, la structure organisationnelle ainsi que les pouvoirs partag茅s de vote/disposition.
Mit Citadel verbundene Einheiten legen einen erheblichen passiven Anteil an Lexeo Therapeutics (LXEO) offen. Gemeinsam melden Citadel Advisors LLC, Citadel Advisors Holdings LP und Citadel GP LLC die wirtschaftliche Eigent眉merschaft von 5.325.269 Aktien, was 9,6 % der ausstehenden Aktien auf vollst盲ndig verw盲sserter Basis von 55.718.516 Aktien entspricht (einschlie脽lich 1.717.302 Aktien, die bei Wandlung von Warrants ausgebbar sind). Citadel Securities-Einheiten melden separat 8.843 Aktien. Kenneth Griffin wird mit 5.334.112 Aktien wirtschaftlich beg眉nstigt dargestellt (ebenfalls 9,6 %). Die Meldung gibt an, dass die Positionen nicht erworben wurden, um Kontrolle zu 盲ndern oder zu beeinflussen, und nennt die meldenden Personen, die Organisationsstruktur sowie gemeinsame Stimm- und Verf眉gungsrechte.
FAQ
How many LXEO shares do Citadel entities report owning?
What percentage of LXEO does the reported position represent?
Does the filing indicate intent to influence control of Lexeo Therapeutics (LXEO)?
Who among the Citadel reporting persons is individually identified as a beneficial owner?
Does the ownership count include potential shares from warrant conversion?
